June 29, 2021
Latham & Watkins advised Rayner and
Phoenix Equity Partners on the sale of a majority interest to CVC Capital
Partners VIII for an undisclosed amount.
Rayner is a manufacturer and developer of
innovative intraocular lenses (IOLs) and associated pharmaceuticals. Rayner’s
products deliver sight-restorative implants and treatments to patients during
cataract and refractive surgeries. Rayner makes these and other products
available to patients in over 80 countries, through its subsidiaries and
distribution networks, to improve the eyesight of more than 300,000 patients
per year.
The transaction is expected to close in Q3
2021, subject to customary closing conditions and receipt of required
regulatory approvals.
The Latham team was led by London corporate
partners Robbie McLaren and Farah O’Brien, with associates Gillian Bourke and
Róisín Mbonu.